Biologically Active Substance – Page 28

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

12 months ago talkbio0Tagged 4-year, Approved, blockbuster drug, Clinical Trials, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.

Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis

12 months ago talkbio0Tagged Analysis of substances, Cardiovascular Diseases, Diabetes, Long-term, Nordisk, Obesity, semaglutide, Wegovy, Weight Loss

Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

12 months ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Attovia Secures $105M for Multiple Trials of Innovative Industrial and Institutional Biologics

12 months ago talkbio0Tagged Attovia, Biological Factors, Clinical Trials, crossover investors, Industry, institutional

Attovia, biologics, industrial and institutional (I&I), crossover investors, funding, clinical trials

Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits

12 months ago talkbio0Tagged Biological Factors, CBER, healthcare innovation, Measures, Medical Devices, Peter Marks, Prophylactic behavior, public health medicine (field), Regulatory Affairs, United States Food and Drug Administration, Vaccines

CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.

Prologue Ventures: Revolutionizing Viral Protein Drug Development with $50 Million Investment

12 months ago talkbio0Tagged Biotechnology, Drug Development, healthcare innovation, Investments, Prologue Ventures, Viral Proteins

Prologue Ventures, viral protein drugs, $50 million investment, drug development, biotechnology, healthcare innovation.

What is the difference between prime editing and CRISPR/Cas9

12 months ago talkbio0Tagged CRISP, Prime Editing

The difference between Prime Editing and CRISPR/Cas9 lies in their mechanisms of editing DNA, their efficiency, precision, and the types of genetic modifications they can achieve. Mechanism of Editing Efficiency and Precision Types of Genetic Modifications In summary, while both Prime Editing and CRISPR/Cas9 are groundbreaking genome editing tools, Prime Editing offers a more precise […]